Skip to main content



Page 1 of 20

  1. Content type: Research article

    Olanzapine is an atypical antipsychotic drug with high clinical efficacy, but which can cause severe weight gain and metabolic disorders in treated patients. Blockade of the histamine 1 (H1) receptors is believed...

    Authors: Somayeh Jafari, Marc E Bouillon, Xu-Feng Huang, Stephen G Pyne and Francesca Fernandez-Enright

    Citation: BMC Pharmacology 2012 12:8

    Published on:

  2. Content type: Research article

    Lysophosphatidic acid (LPA) is a signalling phospholipid with multiple biological functions, mainly mediated through specific G protein-coupled receptors. Aberrant LPA signalling is being increasingly implicat...

    Authors: Niina Aaltonen, Marko Lehtonen, Katri Varonen, Gemma Arrufat Goterris and Jarmo T Laitinen

    Citation: BMC Pharmacology 2012 12:7

    Published on:

  3. Content type: Research article

    Nor-BNI, GNTI and JDTic induce κ opioid antagonism that is delayed by hours and can persist for months. Other effects are transient. It has been proposed that these drugs may be slowly absorbed or distributed,...

    Authors: Thomas A Munro, Loren M Berry, Ashlee Van’t Veer, Cécile Béguin, F Ivy Carroll, Zhiyang Zhao, William A Carlezon Jr and Bruce M Cohen

    Citation: BMC Pharmacology 2012 12:5

    Published on:

  4. Content type: Research article

    Serotonin (5-hydroxytryptamine; 5-HT) delivered over 1 week results in a sustained fall in blood pressure in the sham and deoxycorticosterone acetate (DOCA)-salt rat. We hypothesized 5-HT lowers blood pressure...

    Authors: Robert Patrick Davis, Jill Pattison, Janice M Thompson, Ruslan Tiniakov, Karie E Scrogin and Stephanie W Watts

    Citation: BMC Pharmacology 2012 12:4

    Published on:

  5. Content type: Research article

    Linaclotide has been proposed as a treatment for the same gastrointestinal indications for which lubiprostone has been approved, chronic idiopathic constipation and irritable bowel syndrome with constipation. ...

    Authors: John Cuppoletti, Anthony T Blikslager, Jayati Chakrabarti, Prashant K Nighot and Danuta H Malinowska

    Citation: BMC Pharmacology 2012 12:3

    Published on:

  6. Content type: Research article

    Dipeptidylpeptidase 4 (DPP4) inhibitors have clinical benefit in patients with type 2 diabetes mellitus by increasing levels of glucose-lowering incretin hormones, such as glucagon-like peptide -1 (GLP-1), a p...

    Authors: Aiying Wang, Charles Dorso, Lisa Kopcho, Gregory Locke, Robert Langish, Eric Harstad, Petia Shipkova, Jovita Marcinkeviciene, Lawrence Hamann and Mark S Kirby

    Citation: BMC Pharmacology 2012 12:2

    Published on:

  7. Content type: Research article

    The emergence of Multi-drug resistant tuberculosis in pandemic proportions throughout the world and the paucity of novel therapeutics for tuberculosis have re-iterated the need to accelerate the discovery of n...

    Authors: Vinita Periwal, Shireesha Kishtapuram and Vinod Scaria

    Citation: BMC Pharmacology 2012 12:1

    Published on:

  8. Content type: Research article

    When stimulated by small molecular agonists, the A3 adenosine receptor (AR) mediates cardioprotective effects without inducing detrimental hemodynamic side effects. We have examined pharmacologically the protecti...

    Authors: Tina C Wan, Dilip K Tosh, Lili Du, Elizabeth T Gizewski, Kenneth A Jacobson and John A Auchampach

    Citation: BMC Pharmacology 2011 11:11

    Published on:

  9. Content type: Research article

    Under conditions of cardiovascular dysfunction, protease-activated receptor 2 (PAR2) agonists maintain vasodilatation activity, which has been attributed to increased cyclooxygenase-2, nitric oxide synthase an...

    Authors: Elizabeth Chia, Satomi Kagota, Enoka P Wijekoon and John J McGuire

    Citation: BMC Pharmacology 2011 11:10

    Published on:

  10. Content type: Erratum

    Authors: Wiebke Janssen, Yves Schymura, Astrid Wietelmann, Johannes-Peter Stasch, Himal Luitel, Norbert Weissmann, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Thomas Braun, Werner Seeger and Ralph Theo Schermuly

    Citation: BMC Pharmacology 2011 11(Suppl 1):P80

    Published on:

    This article is part of a Supplement: Volume 11 Supplement 1

    The original article was published in BMC Pharmacology 2011 11:P79

  11. Content type: Meeting abstract

    Authors: Zsófia Kohajda, Attila Kristóf, Péter P Kovács, Claudia Corici, László Virág, Viktor Juhász, Zoltán Husti, István Baczkó, András Varró and Norbert Jost

    Citation: BMC Pharmacology 2011 11(Suppl 2):A60

    Published on:

    This article is part of a Supplement: Volume 11 Supplement 2

  12. Content type: Meeting abstract

    Authors: Gabriella Juhasz-Vedres, Anja Scharinger, Mathias Gebhart, Perrine Busquet, Chiara Poggiani, Simone B Sartori, Martina J Sinnegger-Brauns, Alexandra Koschak and Jörg Striessnig

    Citation: BMC Pharmacology 2011 11(Suppl 2):A44

    Published on:

    This article is part of a Supplement: Volume 11 Supplement 2

  13. Content type: Meeting abstract

    Authors: Yu Kasugai, Elisabeth Vogel, Markus Hauschild, Ramon O Tasan, Yvan Peterschmitt, Andreas Lüthi, Ryuichi Shigemoto, Werner Sieghart, Nicolas Singewald, Günther Sperk and Francesco Ferraguti

    Citation: BMC Pharmacology 2011 11(Suppl 2):A42

    Published on:

    This article is part of a Supplement: Volume 11 Supplement 2

  14. Content type: Meeting abstract

    Authors: Florian Buchmayer, Klaus Schicker, Gerald Stübiger, Peter J Hamilton, Petra Geier, Andreas Jurik, René Weissensteiner, Thomas Steinkellner, Heinrich J Matthies, Therese Montgomery, Marie-Therese Winkler, Jae-Won Yang, Marion Holy, Gerhard F Ecker, Aurelio Galli, Valery Bochkov…

    Citation: BMC Pharmacology 2011 11(Suppl 2):A19

    Published on:

    This article is part of a Supplement: Volume 11 Supplement 2